Patent Daily RSS
Twitter Guna
- Access the Bayer’s appeal - bit.ly/Lj9RMP 6 days ago
- Bayer seeks to stay the operation of the CL order - bit.ly/JBAlIS 6 days ago
- USPTO Offers Patent Applicants Option to Supplement Disclosure of Prior Art After Paying Issue Fee - bit.ly/Ju5BYd 1 week ago
- Piramal Healthcare to buy US firm to boost R&D - bit.ly/MiVA1V 1 week ago
- Financial challenges, novel drug devpt pressures to hamper India’s R&D growth: Expert - bit.ly/JHsWnw 1 week ago
- Biotech body criticises Bayer on cancer drug - bit.ly/J5DEpF 1 week ago
- India drugs inquiry could prompt new U.S. scrutiny - reut.rs/JDVT5y 1 week ago
- Cipla breached patent rights by slashing cancer drug price: Bayer - bit.ly/JyCBys 2 weeks ago
- No pharma application pending for compulsory licence: Govt - bit.ly/K3OUQy 2 weeks ago
- India’s patent protection regime to be key issue in talks with US - bit.ly/Jfhluh 2 weeks ago
Monthly Archives: July 2011
India – Section 16 – Divisional applications
We aware that the new manual issued recently by IPO India, includes new guidelines and best practices for filing and prosecuting divisional applications. Some of the recent decisions from IPO are in line with this. (a) A divisional application should … Continue reading
Posted in Uncategorized
1 Comment
Gilead – HIV Treatment – Indian companies
[businesswire] Gilead Sciences, Inc. announced today an expansion of its global access program in an effort to provide accelerated access to Gilead medicines for the treatment of HIV/AIDS. The changes announced today include new licensing terms with four India-based drug … Continue reading
Posted in Daily interesting IP news
Tagged Gilead, Hetero, HIV treatment, Matrix, Ranbaxy, Strides
Leave a comment
Yasmin patent revoked in Europe
[Fox business] EPO revokes EP1214076B1 patent relates to Formulation of Yasmin product and it is equivalent of US6787531 (Not updated in register Plus). This decision came from appeal filed by Hexal against Opposition board decision. The same patent’s equivalent (IN/PCT/2002/410/CHE) … Continue reading